A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)

  • Renal Cell Cancer (RCC)
Trial Status:

Completed

This trial runs in
Countries
  • Australia
  • Bosnia and Herzegovina
  • Brazil
  • Canada
  • Czechia
  • Denmark
  • France
  • Germany
  • Italy
  • Japan
  • Mexico
  • Poland
  • Russia
  • Singapore
  • South Korea
  • Spain
  • Taiwan
  • Thailand
  • Turkey
  • United Kingdom
  • United States
Trial Identifier:

NCT02420821 2014-004684-20 WO29637

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic RCC who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT02420821 , WO29637 , 2014-004684-20 Trial Identifier
      Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Bevacizumab, Sunitinib Treatments
      Renal Cell Carcinoma Condition
      Official Title

      A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Definitive diagnosis of unresectable locally advanced or metastatic RCC with clear-cell histology and/or a component of sarcomatoid carcinoma, with no prior treatment in the metastatic setting
      • Evaluable Memorial Sloan Kettering Cancer Center risk score
      • Measurable disease, as defined by RECIST v1.1
      • Karnofsky performance status greater than or equal to 70%
      • Adequate hematologic and end-organ function prior to randomization
      Exclusion Criteria

      Disease-Specific Exclusions:

      • Radiotherapy for RCC within 14 days prior to treatment
      • Active central nervous system disease
      • Uncontrolled pleural effusion, pericardial effusion, or ascites
      • Uncontrolled hypercalcemia
      • Any other malignancies within 5 years except for low-risk prostate cancer or those with negligible risk of metastasis or death

      General Medical Exclusions:

      • Life expectancy less than 12 weeks
      • Participation in another experimental drug study within 4 weeks prior to treatment
      • Pregnant or lactating women
      • Known hypersensitivity to any component of atezolizumab or other study medication
      • History of autoimmune disease except controlled, treated hypothyroidism or type I diabetes mellitus
      • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis
      • Positive human immunodeficiency virus test
      • Active or chronic hepatitis B or C
      • Severe infections within 4 weeks prior to treatment
      • Exposure to oral or IV antibiotics within 2 weeks prior to treatment
      • Live attenuated vaccines within 4 weeks prior to treatment (for influenza vaccination participants must agree not to receive live, attenuated influenza vaccine within 4 weeks prior to treatment, during treatment or within 5 months following the last dose)
      • Significant cardiovascular disease
      • Prior allogeneic stem cell or solid organ transplantation

      Exclusion Criteria Related to Medications:

      • Prior treatment with cluster of differentiation 137 agonists, anti-cytotoxic T-lymphocyte associated protein-4, anti-programmed death (PD)-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
      • Treatment with immunostimulatory agents for non-malignant conditions within 6 weeks or immunosuppressive agents within 2 weeks prior to treatment

      Bevacizumab- and Sunitinib-Specific Exclusions:

      • History of hypertensive crisis or hypertensive encephalopathy
      • Baseline electrocardiogram showing corrected QT interval greater than 460 milliseconds

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now